ReviewLeukemia2024
Measurable residual disease (MRD)-testing in haematological and solid cancers.
Review in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Harnessing Endogenous Plasticity Rather than Reprogramming of Mature Cells Will Advance Regenerative Medicine, Cancer Treatment and Rejuvenation.Stem cell reviews and reports · 2026Review
- Measurable Residual Disease and the Unresolved Biology of Leukemic Stem Cells.Stem cell reviews and reports · 2026Review
- MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer.NPJ precision oncology · 2026Article
- Oxidative Stress-Guided Gold Nanoparticles for Cancer Theranostics.Antioxidants (Basel, Switzerland) · 2026Review
- Harmonising ctDNA Measurement in Haematological Malignancies: Traceability, Commutability and Reporting.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Physician-complementing artificial intelligence in haematology: ushering in a new era.Leukemia · 2026Review
- Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment.Translational oncology · 2026Review
- Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.Molecular cancer · 2026Review
- Review
- False-Positive and False-Negative MRD Results in Children with Acute Lymphoblastic Leukemia: Navigating Between Scylla and Charybdis (Brief Review and Clinical Experience).Children (Basel, Switzerland) · 2025Review
- An Update on Flow Cytometry Analysis of Hematological Malignancies: Focus on Standardization.Cancers · 2025Review
- A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.NPJ precision oncology · 2025Article
- A heterotrimeric G protein (Gsα) biomarker may predict antidepressant response in subjects with major depressive disorder.Frontiers in psychiatry · 2025Article
- Mutations and MRD: clinical implications of clonal ontogeny.Hematology. American Society of Hematology. Education Program · 2024Review
- Measurable Residual Disease in Hematological Cancers.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.